QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Inebilizumab Pharmacovigilance Across NMOSD, IgG4-RD and Generalized Myasthenia Gravis

Test your understanding of the concepts covered by Inebilizumab: CD19 B-Cell Depletion Across NMOSD, IgG4-RD and gMG.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which product-exposure detail most directly supports a cluster investigation or potential quality assessment?

The patient's preferred vaccination brand The product brand and batch or lot number The patient's baseline neurological examination alone The date of disease diagnosis without treatment dates

Question 2 of 10 Why is the distinction between CD19 and CD20 clinically relevant to pharmacovigilance?

All B-cell-depleting products have identical immune effects, so the distinction is mainly nomenclature Different target expression patterns can alter the populations depleted and therefore influence immunoglobulin effects, efficacy interpretation and infection risk CD19-directed treatment cannot cause infection because it does not affect plasma-cell biology CD20-directed treatment is limited to neurological diseases, whereas CD19-directed treatment is limited to systemic diseases

Question 3 of 10 Why should indication be retained as a key variable when analysing infections across inebilizumab cases?

The indication determines the product lot number NMOSD, IgG4-RD and gMG populations may differ in disease manifestations, prior corticosteroid exposure and other immunosuppressive treatments Indication has no effect on background risk but is required only for administrative coding Different indications receive entirely unrelated active ingredients

Question 4 of 10 In AQP4-IgG-positive NMOSD, what is the main therapeutic objective of B-cell depletion?

Repair established optic-nerve and spinal-cord lesions Reduce the cellular source and support system for pathogenic antibody responses and prevent future attacks Increase acetylcholine receptor density at the neuromuscular junction Reverse fibrosis in affected abdominal organs

Question 5 of 10 Which pre-treatment assessment is specifically important because B-cell depletion may increase the risk of hepatitis B reactivation?

Hepatitis B screening and appropriate baseline serological assessment Routine measurement of acetylcholine receptor density A baseline pulmonary function test in every patient as the only screening measure A skin-prick test for infusion-related anxiety

Question 6 of 10 Which case-processing sequence best follows the article's practical assessment framework?

Assign causality first, then determine the indication and reconstruct exposure Confirm indication and antibody status, reconstruct dosing, establish immune baseline, define the event clinically, and assess confounders Code every post-infusion symptom as lack of efficacy Focus on the latest infusion only and disregard prior immunoglobulin and infection data

Question 7 of 10 Which set of information would provide the strongest assessment of a suspected HBV reactivation case during inebilizumab therapy?

Only the date of the most recent infusion Baseline HBV serology, HBV DNA where available, liver tests, prophylaxis and timing relative to B-cell depletion Only the patient's disease indication and age The infusion rate and premedication without virological data

Question 8 of 10 A patient experiences a serious infection several weeks after an inebilizumab infusion. Which attribution principle is most appropriate?

The event cannot be related because it did not occur during the infusion The event should be assessed in light of persistent B-cell depletion, immunoglobulin status and concomitant immunosuppression The event should automatically be attributed to the patient's underlying disease Only the serum concentration measured on the day of infection is relevant

Question 9 of 10 A patient with profound immunomodulation develops new unexplained neurological deterioration. Which action is most appropriate when considering PML?

Assume it is an NMOSD relapse and do not investigate further Assume it is an infusion reaction because the patient received an antibody Pursue a careful differential diagnosis, including MRI and cerebrospinal-fluid testing where clinically appropriate Exclude PML because no confirmed product-specific causal pattern is established

Question 10 of 10 Which information is most useful for assessing a suspected infusion reaction?

Infusion number, onset relative to infusion, premedication, infusion rate, clinical features and management Only the patient's baseline IgG concentration Only the indication, without any timing information The number of previous disease relapses but not the event chronology

Knowledge Assessment: Inebilizumab Pharmacovigilance Across NMOSD, IgG4-RD and Generalized Myasthenia Gravis

Cookie Settings